CRDF - Rasio rega marang prakiraan pendapatan Cardiff Oncology Inc.

Cardiff Oncology (CRDF) - logo korporat

Cardiff Oncology, Inc. (CRDF) possesses a significant pricing power advantage due to its unique PLK1 inhibitor that overcomes tumor resistance. The expected revenue multiple clearly demonstrates market expectations, where 101.30 represents the current level of the metric. Phase 2 trials for colorectal cancer and the search for partners support the growth in market capitalization. An emphasis on a breakthrough R&D pipeline completes the company's strategy to combat severe forms of diseases.

Cardiff Oncology Corp - Prakiraan rega marang pendapatan CRDF (periode 04.07.2022 - 15.11.2026)

Rincian metrik komprehensif lan analitis Cardiff Oncology Corp (CRDF)

Analisis umum perusahaan:Cardiff Oncology CRDF
Produk sing diprodhuksi Cardiff Oncology Inc.

High barriers to entry in the targeted oncology sector, driven by patent protection and R&D costs, make the valuation of Cardiff Oncology, Inc. (CRDF) extremely sensitive to future sales expectations. The forward P/S multiple reflects the current premium to expected revenue, allowing investors to promptly assess capitalization without reporting lags and determine the fairness of the asset's price relative to business growth rates.

Pesaing wigati

Rasio rega marang prakiraan pendapatan Incyte Corp. INCY|HUTCHMED Ltd (HCM) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|NUVB - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Day One|MNPR: Multiplikator Forward P/S|Prakiraan rega marang pendapatan Inhibrx Biosciences Inc INBX|Multiplikator forward rega marang pendapatan IMAB|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Fennec Pharmaceuticals FENC|Multiplikator forward rega marang pendapatan HRTX (Heron)|NVCT (Nuvectis Pharma) - Rega forward marang dodolan|Coherus Biosciences - Multiplikator forward rega marang pendapatan|Rasio rega marang pendapatan sing dikarepake CRBP (Corbus Pharmaceuticals Holdings)|BeyondSpring Pharma - Multiplikator Forward P/S|Rega forward marang dodolan BCAB (bioatla.com)|LIXT: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Citius Pharma (CTXR)|Rasio rega marang prakiraan pendapatan Cellectar Biosciences, Inc.|BLRX: Rega forward marang dodolan|Multiplikator Forward P/S CANF|Multiplikator Forward P/S Aprea Therapeutics Inc. (APRE)|Rasio rega marang prakiraan pendapatan Kazia Therapeutics Ltd KZIA|SLXN (silexion.com) - Rega mangsa ngarep marang pendapatan|NCNA: Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Chimerix|CYCC: Multiplikator Forward P/S|Prakiraan rega marang pendapatan G1 Therapeutics Inc. GTHX|Rasio rega marang prakiraan pendapatan Kronos Bio, Inc.|kintara.com (KTRA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator Forward P/S ONCT|PRTG (Portage) - Rega forward marang dodolan